Atorvastatin

Contraindicated

Atorvastatin Colchicine Colcrys Increased colchicine exposure, an increased risk of colchicine toxicity and an increased risk of myopathy and rhabdomyolysis Details Atorvastatin Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Atorvastatin Erythromycin Erythrocin Stearate Increased atorvastatin exposure, an increased risk of atorvastatin-related adverse reaction and an increased risk of myopathy or r... Details Atorvastatin Lonafarnib Zokinvy Increased atorvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Atorvastatin Posaconazole Noxafil Increased atorvastatin exposure, an increased posaconazole exposure and an increased risk of myopathy and rhabdomyolysis Details Atorvastatin Ritonavir Norvir Increased atorvastatin exposure and an increased risk of myopathy, including rhabdomyolysis Details

Major

Atorvastatin Abametapir Increased exposure of CYP3A4 substrate Details Atorvastatin Relugolix Orgovyx Increased relugolix exposure Details Atorvastatin Alfentanil Increased ALfentanil exposure and an increased risk of respiratory depression Details Atorvastatin Amprenavir Increased atorvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Atorvastatin Apalutamide Erleada Reduced OATP1B1/CYP3A4 substrate exposure Details Atorvastatin Artemether Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Atorvastatin Atazanavir Reyataz Increased risk of atorvastatin toxicity, including an increased risk of myopathy or rhabdomyolysis Details Atorvastatin Avacopan Tavneos Increased CYP3A4 substrate exposure Details Atorvastatin Bezafibrate Increased incidence and severity of myopathy Details Atorvastatin Boceprevir Increased atorvastatin exposure Details Atorvastatin Carbamazepine Carbatrol Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Atorvastatin Ceftobiprole Medocaril Increased OATP1B1 substrate exposure and an increased OATP1B3 substrate exposure Details Atorvastatin Ceritinib Zykadia Increased CYP3A substrate exposure Details Atorvastatin Ciprofibrate An increased risk of myopathy or rhabdomyolysis Details Atorvastatin Ciprofloxacin An increased risk of myopathy or rhabdomyolysis Details Atorvastatin Clarithromycin Biaxin Increased atorvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Atorvastatin Clofibrate An increased risk of myopathy and rhabdomyolysis Details Atorvastatin Cobicistat Tybost Increased cobicistat exposure, an increased atorvastatin exposure and an increased risk of myopathy Details Atorvastatin Conivaptan Vaprisol Increased CYP3A substrate exposure Details Atorvastatin Cyclosporine Atopica Increased atorvastatin exposure, an increased risk of myopathy or rhabdomyolysis and an increased cycloSPORINE exposure Details Atorvastatin Dabrafenib Tafinlar Reduced sensitive CYP3A4 substrate exposure Details Atorvastatin Dalfopristin An increased risk of myopathy or rhabdomyolysis Details Atorvastatin Danazol Danocrine® An increased risk of myopathy or rhabdomyolysis Details Atorvastatin Daptomycin Cubicin Increased risk of myopathy or rhabdomyolysis Details Atorvastatin Darolutamide Nubeqa Increased exposure of OATP1B1 or OATP1B3 substrates Details Atorvastatin Darunavir Increased atorvastatin exposure, an increased darunavir exposure and an increased risk of myopathy or rhabdomyolysis Details Atorvastatin Digoxin Cardoxin® Increased digoxin exposure Details Atorvastatin Diltiazem Cardizem Increased atorvastatin exposure, an increased risk of rhabdomyolysis and an increased dilTIAZem exposure Details Atorvastatin Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Atorvastatin Doxorubicin Hydrochloride Liposome Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Atorvastatin Elafibranor Iqirvo Increased risk of CPK elevation/myalgia and an increased risk of myopathy Details Atorvastatin Elbasvir Increased atorvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Atorvastatin Elexacaftor Increased OATP1B1/OATP1B3 substrate exposure Details Atorvastatin Eltrombopag Alvaiz Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details